Related Experiment Video
Updated: Aug 19, 2026
Studying Microbial Communities In Vivo: A Model of Host-mediated Interaction Between Candida Albicans and Pseudomonas Aeruginosa in the Airways
Published on: January 13, 2016
A prospective study of lung disease caused by Mycobacterium avium/Mycobacterium intracellulare
Abstract:
This is a prospective study of 36 patients with lung infections caused by M. avium/M. intracellulare. The division of the patients into 2 prognostic groups ("good"/"others"), and the guidelines for their treatment are based on a previous report (3). The criteria for the division were co-existing lung disease and dyspnoea on admittance. The patients in group "good" were treated with isoniazid, rifampicin and ethambutol, in group "others" these were supplemented with one or more drugs. As in the previous study (3), the prognosis was far better for group "good" than for group "others". The patients in group "good" should be treated with isoniazid, rifampicin and ethambutol, unless the course of disease is unsatisfactory. The mortality was high in group "others" and half of the deaths were related to mycobacteriosis. Some patients became culture negative and others showed decreasing numbers of bacteria, but the value of the supplementary drugs could not be proven.
Insights
This study on lung infections caused by Mycobacterium avium complex (MAC) found that patients with good prognostic factors had better outcomes with standard treatment. Patients with poor prognostic factors faced higher mortality despite additional drugs.
Area of Science:
- Pulmonology
- Infectious Diseases
- Microbiology
Background:
- Lung infections caused by Mycobacterium avium complex (MAC) present a significant clinical challenge.
- Treatment strategies and prognostic factors for MAC lung disease require ongoing investigation.
Purpose of the Study:
- To evaluate treatment outcomes for patients with lung infections caused by Mycobacterium avium/intracellulare.
- To assess the impact of prognostic factors on treatment efficacy and patient survival.
Main Methods:
- A prospective study involving 36 patients with MAC lung infections.
- Patients were categorized into two prognostic groups: 'good' and 'others', based on co-existing lung disease and dyspnea.
- Treatment regimens varied, with the 'others' group receiving additional antimicrobial agents.
Main Results:
- The 'good' prognostic group demonstrated significantly better outcomes compared to the 'others' group.
- High mortality rates were observed in the 'others' group, with mycobacteriosis contributing to half of the deaths.
- While some patients achieved negative cultures or reduced bacterial loads, the benefit of supplementary drugs in the 'others' group was not definitively proven.
Conclusions:
- Standard treatment (isoniazid, rifampicin, ethambutol) is recommended for patients with good prognostic factors in MAC lung disease.
- Patients with poor prognostic factors face a worse prognosis and high mortality, warranting further research into optimal therapeutic approaches.
- The efficacy of additional antimicrobial agents beyond the standard regimen for severe MAC lung disease remains uncertain.
